SynBiotic SE (DUSE:SBX)
Germany · Delayed Price · Currency is EUR | Market Cap | 6.82M -67.6% |
| Revenue (ttm) | 14.86M +171.5% |
| Net Income | -9.72M |
| EPS | -1.66 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,600 |
| Open | 0.6030 |
| Previous Close | n/a |
| Day's Range | 0.6030 - 0.7210 |
| 52-Week Range | 0.6030 - 3.7100 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 6.05 (+739.11%) |
| Earnings Date | Nov 16, 2026 |
About SynBiotic SE
SynBiotic SE, together with its subsidiaries, engages in the pharmaceutical business in Germany and Europe. It is involved in the cultivation, research, development, production, and distribution of medicinal cannabis; industrial hemp; and cannabidiol and cannabinoid-based products. The company was incorporated in 2024 and is based in Düsseldorf, Germany. [Read more]
Financial Performance
In 2024, SynBiotic SE's revenue was 14.86 million, an increase of 269.31% compared to the previous year's 4.02 million. Losses were -9.72 million, -8.60% less than in 2023.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for SBX stock is "Strong Buy." The 12-month stock price target is €6.05, which is an increase of 739.11% from the latest price.
News
Portfolio unwound; rating placed Under Review: Wave of portfolio insolvencies narrows SYNBIOTIC to WEECO ...
SYNBIOTIC's investment case has changed fundamentally after a wave of insolvencies and liquidations across the portfolio. What began with the Bushdoctor (Austria) insolvency in December 2025 has wi...
Portfolio unwound; rating placed Under Review
Wave of portfolio insolvencies narrows SYNBIOTIC to WEECO Pharma as sole core asset; rating and PT placed Under Review pending audited accounts and funding clarity.